跳至主要内容
临床试验/EUCTR2018-000201-24-ES
EUCTR2018-000201-24-ES进行中(未招募)1 期

Effectiveness and cost-effectiveness of Ozone therapy in patients with ischemic heart disease refractory to medical and surgical treatment: Randomized, triple-blind clinical trial. - O3Cardio

Bernardino Clavo - Hospital Dr. Negrín0 个研究点目标入组 18 人开始时间: 2018年6月21日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
18

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • -Adults with chronic heart failure Functional Class III-IV from the NYHA, with symptoms in spite of maximal conventional medical treatment and no suitable to further percutaneous or surgical procedures.
  • -Age: 18 to 80 years old
  • -It should be required clinical diagnosis by Cardiology Department and confirmation by cardiac catheterization with coronary angiography.
  • -Ejection Fraction < 35%
  • -Patients who have signed and dated the study 's specific informed consent.
  • -Pregnant women can not participate in the clinical trial.
  • -Before enrollment, women of childbearing potential should obtain a negative result in the serum or urine pregnancy test at the screening visit, and accept the use of appropriate contraceptive methods at least from the 14 days prior to the first dose of the study drug. up to 14 days after the last one.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 9
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 9

排除标准

  • -Pregnancy at the time of enrollment.
  • -Age < 18 or > 80 years old.
  • -Limited walking ability due to neurologic or orthopedic impairments of the legs
  • -Those who are uncapable to fill in the scales used to measure quality of life variables
  • -Cerebral vascular accident (CVA or Transient Ischemic Attack (TIA) within the previous 3 months or carotid stenosis > 80%.
  • -Acute myocardial infarction (AMI), Percutaneous coronary intervention (PCI) or transmyocardial laser revascularization (TMR or PMR) within the previous 3 months.
  • -Hemodynamically or clinically unstable patients.
  • -Severe or limiting pulmonary diseases.
  • -Specific liver enzymes [Aspartate Aminotransferase (AST), and Alanine Aminotransferase (ALT) > 5 times the upper limit of normal
  • -Increased creatinine > 3 times the upper limit of normal or Glomerular Filtration Rate (GFR) < 25 ml/min or who are on chronic renal dialysis.
  • -Severe peripheral vascular disease with rest pain or significant chronic wounds.
  • -Uncontrolled cancer disease or severe active systemic infection or HIV.
  • -Life expectancy < 4 months
  • -Contraindication or disability for rectal ozone administration or to attend scheduled treatments.
  • -Known allergy to ozone.
  • -Patients who do not meet all the inclusion criteria.

研究者

发起方
Bernardino Clavo - Hospital Dr. Negrín

相似试验